Kyowa Hakko U.S.A. Introduces Cognizin™ For Brain Health
October 7, 2003
Cognizin™ becomes first branded ingredient for international health ingredients manufacturer
New York, N.Y. – Kyowa Hakko U.S.A., Inc. announced at SupplySide West in Las Vegas it has trademarked its novel and powerful anti-aging Citicoline ingredient under the brand name of Cognizin™. Citicoline has been used in the treatment of neurodegenerative disorders associated with stroke, cerebrovascular pathology, brain aging and head trauma. Scientific studies have indicated effectiveness in treating Alzheimer’s and Parkinson’s disease and improved stroke recuperation, as well as glaucoma.
Dr. Alexander G. Schauss, PhD, director, Natural and Medicinal Products Research, Life Sciences Division, American Institute for Biosocial and Medical Research Inc., and leading scientific expert on the health benefits of Citicoline, has been a major proponent of Citicoline use.
At a SupplySide West science seminar attended by over 40 leading nutraceutical industry companies, Dr. Schauss discussed the capabilities Citicoline has shown in reversing memory loss and its ability to mitigate cardiovascular pathologies such as stroke which contributes to the loss of brain function.
Kyowa Hakko is one of the world leaders in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. The company has developed new commercial production techniques of Citicoline using fermentation technology.